Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2014 | 1 |
2015 | 1 |
2016 | 1 |
2017 | 2 |
2018 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8.
Lancet HIV. 2017.
PMID: 28495562
Free PMC article.
Clinical Trial.
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.
Hakim JG, et al.
Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3.
Lancet Infect Dis. 2018.
PMID: 29108797
Free PMC article.
Clinical Trial.
Item in Clipboard
Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index.
Shi Y, Thompson J, Walker AS, Paton NI, Cheung YB; EARNEST Trial Team.
Shi Y, et al.
Health Qual Life Outcomes. 2019 May 10;17(1):83. doi: 10.1186/s12955-019-1135-8.
Health Qual Life Outcomes. 2019.
PMID: 31077251
Free PMC article.
Clinical Trial.
Item in Clipboard
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team.
Paton NI, et al.
N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274.
N Engl J Med. 2014.
PMID: 25014688
Free article.
Clinical Trial.
Item in Clipboard
Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.
Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, Nahirya Ntege P, Gibb DM, Thiebaut R, Walker AS, Klein N, Callard R; ARROW Trial Team.
Picat MQ, et al.
PLoS Med. 2013 Oct;10(10):e1001542. doi: 10.1371/journal.pmed.1001542. Epub 2013 Oct 29.
PLoS Med. 2013.
PMID: 24204216
Free PMC article.
METHODS AND FINDINGS: CD4 counts every 12 wk over a median (interquartile range) of 4.0 (3.7, 4.4) y in 1,206 HIV-infected children, aged 0.4-17.6 y, starting ART in the Antiretroviral Research for Watoto trial (ISRCTN 24791884) were analysed in an exploratory analysis supplement …
METHODS AND FINDINGS: CD4 counts every 12 wk over a median (interquartile range) of 4.0 (3.7, 4.4) y in 1,206 HIV-infected children, aged 0. …
Item in Clipboard
Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.
Arenas-Pinto A, Thompson J, Musoro G, Musana H, Lugemwa A, Kambugu A, Mweemba A, Atwongyeire D, Thomason MJ, Walker AS, Paton NI; EARNEST Trial Team.
Arenas-Pinto A, et al.
J Neurovirol. 2016 Feb;22(1):104-13. doi: 10.1007/s13365-015-0374-7. Epub 2015 Aug 25.
J Neurovirol. 2016.
PMID: 26323809
Clinical Trial.
Item in Clipboard
Cite
Cite